Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics develops messenger RNA medicines focused on liver and respiratory rare diseases, including candidates for ornithine transcarbamylase deficiency and cystic fibrosis, and vaccines for infectious diseases. Its pipeline includes ARCT-810, an mRNA therapeutic candidate for OTC deficiency, and ARCT-032, an inhaled mRNA candidate for cystic fibrosis. Arcturus uses its LUNAR lipid nanoparticle delivery system and STARR self-amplifying mRNA platform to develop therapeutics and vaccines. Arcturus also partners with CSL Seqirus to develop and commercialize mRNA vaccines for COVID-19, influenza and other infectious diseases. KOSTAIVE, its self-amplifying mRNA COVID-19 vaccine, is approved in Japan, the European Union and the United Kingdom, and commercial sales began in Japan in October 2024 through Meiji. Arcturus is headquartered in San Diego, California.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $ARCT in the last 30 days.
See all $ARCT insider activity →Arcturus Therapeutics (ARCT) plans to begin Phase II dosing of ARCT-2601 next quarter, with top line data expected in the second half of 2027. This follows a 38-fold potency gain in their LUNAR 2.0 delivery platform, announced during their Q3 2026 earnings call.
Arcturus Therapeutics reported Q3 2026 results, highlighting progress in its pipeline. ARCT-032 Phase 2 enrollment is expected to complete by year-end 2026, with data presentation in Q2 2027. ARCT-2601 Phase 2 dosing is planned for Q1 2027, with top-line data expected in H2 2027. The company also announced a cash runway of over two years through 2028.
A Phase 1 trial of Arcturus Therapeutics' self-amplifying mRNA H5N1 flu vaccine, ARCT-2304, showed strong immune responses and durability when doses were spaced eight weeks apart. The vaccine, encoding both HA and NA antigens, was well-tolerated across dose levels. The study, funded by U.S. HHS, suggests potential for pandemic preparedness.
Over the past 7 days, AlphAI's AI scored 8 news stories mentioning ARCT (Arcturus Therapeutics Holdings Inc.). Coverage has skewed bullish: 7 bullish, 0 neutral, and 1 bearish.
Recent ARCT coverage spans financial news, technology and market movers.
The upcoming Phase II trial could significantly de‑risk the ARCT‑2601 program and drive share price higher if data meet expectations.
Positive clinical updates and cash runway may support near‑term upside, but upcoming data dependencies keep risk elevated.
Positive Phase 1 data may lift ARCT stock as investors view platform as promising for pandemic flu vaccines
The large sell may push ARCT lower as the market absorbs the fund's reduced exposure.
Positive outlook for Arcturus.
AlphAI scores every news story that mentions ARCT with an AI model for sentiment and relevance, and aggregates insider trades from Arcturus Therapeutics Holdings Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Arcturus Therapeutics (ARCT) plans to begin Phase II dosing of ARCT-2601 next quarter, with top line data expected in the second half of 2027. This follows a 38-fold potency gain in their LUNAR 2.0 delivery platform, announced during their Q3 2026 earnings call.
Arcturus Therapeutics reported Q3 2026 results, highlighting progress in its pipeline. ARCT-032 Phase 2 enrollment is expected to complete by year-end 2026, with data presentation in Q2 2027. ARCT-2601 Phase 2 dosing is planned for Q1 2027, with top-line data expected in H2 2027. The company also announced a cash runway of over two years through 2028.
A Phase 1 trial of Arcturus Therapeutics' self-amplifying mRNA H5N1 flu vaccine, ARCT-2304, showed strong immune responses and durability when doses were spaced eight weeks apart. The vaccine, encoding both HA and NA antigens, was well-tolerated across dose levels. The study, funded by U.S. HHS, suggests potential for pandemic preparedness.
FEDERATED HERMES, INC. reduced its stake in Arcturus Therapeutics (ARCT) by 49.21% on Sept. 30, 2026, selling 1.63 million shares at $13.69 each. The firm now holds 1.68 million shares, 5.90% of ARCT's outstanding shares. Arcturus, a clinical-stage mRNA company, has a market cap of $341.93 million and faces valuation concerns, with a GF Value estimate of $2.12, indicating significant overvaluation.
Analysts updated price targets for several companies. Needham raised CrowdStrike's (CRWD) target to $310, Baird increased Humana's (HUM) to $596, and others adjusted targets for Robinhood (HOOD), Webull (BULL), Align (ALGN), Pacira (PCRX), Sailpoint (SAIL), Unity (U), and Arcturus (ARCT). AT&T's (T) target was cut by Scotiabank.
Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.
Biotech stocks APUS, PFSA, GCTK, and ARCT saw notable moves. APUS surged 130% without specific news, plans Phase 3 trial for Apitox. PFSA up 49.14% after ISO 13485 certification progress. GCTK raised $3.1M via stock offering, up 25.62%. ARCT rose 6.77% on Phase 2 results and LUNAR 2.0 platform news. Q2 losses reported for APUS.
Analysts made several rating changes and price target adjustments. JPMorgan upgraded CoreWeave, Welltower, and Macerich, while Citi downgraded Dropbox. Bernstein upgraded Quanta Services, and Morgan Stanley initiated Imax and Nvidia with overweight ratings. Other notable moves include upgrades for Arcturus Therapeutics, Dollar General, and The Brink's Company, and initiations for NeOnc Technologies, Energy Services of America, BayCom, Avidbank, and SpaceX.
Citigroup upgraded Arcturus Therapeutics to Buy from Neutral and raised its price target to $20 from $8. The stock has seen a 5-day change of $13.30, a 1st Jan change of -7.51%, and a 1-year change of +116.97%. The upgrade is based on a weighted average of ratings including valuation, EPS revisions, and visibility.
Arcturus Therapeutics (ARCT) shares rose 5.3% after reporting positive Phase 2 data for ARCT-810 and introducing LUNAR 2.0, a next-gen mRNA platform. The company plans to integrate ARCT-2601 into its Phase 2 study by 2026 and will acquire myNEO to enhance AI-driven mRNA design.
